Methotrexate update.
Methotrexate (MTX) has become one of the most widely prescribed second-line agents world-wide for rheumatoid arthritis (RA). Studies have established efficacy in populations which have failed other second-line agents. Although MTX must be considered as a potential hepatotoxin, studies have shown that liver histologic changes can be predicted by monitoring of serum albumin and AST at four to eight week intervals. MTX pulmonary toxicity appears to be more common than liver disease. It most often presents with a subacute course with dry cough and dyspnea with or without fever. Clinicians must be aware of this presentation and withhold the drug when these symptoms appear. MTX may also cause mild renal impairment when used with NSAIDs. This effect has been observed with higher mean weekly doses in the 15 to 20 mg range, but not with a starting dose of 7.5 mg. Although MTX may exhibit a variety of effects in in vitro systems its mechanism of action in patients with RA has not yet been determined.
Kremer
J M
JM
D000931:Antidotes / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005492:Folic Acid / Q000627:therapeutic use; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D007668:Kidney / Q000187:drug effects; D002955:Leucovorin / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects*; D008168:Lung / Q000187:drug effects*; D008727:Methotrexate / Q000009:adverse effects* / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy
D000931:Antidotes; D018501:Antirheumatic Agents; D003879:Dermatologic Agents; D006397:Hematinics; D005492:Folic Acid; D002955:Leucovorin; D008727:Methotrexate